{"id":117237,"title":"Executive Insights : Interview with Cathal Friel, Chair & Co-Founder of hVIVO PLC","publisher":"Share Talk","author":"sharetalk","published":"2024-10-18T07:24:15+00:00","modified":"2024-10-18T07:50:58+00:00","canonical_url":"https://www.share-talk.com/executive-insights-interview-with-cathal-friel-chair-co-founder-of-hvivo-plc/","markdown_url":"https://www.share-talk.com/executive-insights-interview-with-cathal-friel-chair-co-founder-of-hvivo-plc.md","json_url":"https://www.share-talk.com/executive-insights-interview-with-cathal-friel-chair-co-founder-of-hvivo-plc.json","category":"Exclusive Interviews","categories":["Exclusive Interviews","Health","Healthcare","Pharmaceutical"],"tags":["Andrew Catchpole","antiviral","breast cancer","Canary Wharf","Cathal Friel","CHIMagents","clinical respiratory drug","Codagenix","COVID-19","Dengue Fever","Dr Andrew Catchpole","Dr Chris Chiu","Gregory Stoloff","hVIVO","Imperial College London","Imutex Ltd","laboratory","Malaria","Open Orphan","ORPH","Oxford BioTherapeutics","pharmaceutical","quarantine clinic","Rahim Fandi","Share Talk","Stephen Pinkerton","The Lancet","Vaccine","virology","West Nile Virus","Yamin 'Mo' Khan","Zika"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2024/10/Image-2024-10-18-at-8.22.19-AM.webp?fit=1200%2C576&quality=80&ssl=1","format":"news","language":"en-GB","content":"Interview with Cathal Friel, Chair & Co-Founder of hVIVO PLC, by Brian Egan, Partner at KPMG Ireland Discover how to scale a company from startup to billion-euro enterprise with Cathal Friel, the entrepreneur behind five London Stock Exchange listings and a €1.5B acquisition.\n\nNotes to Editors\n\nAbout hVIVO\n\n[hVIVO plc](http://www.hvivo.com/) (ticker: HVO) is a fast-growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.\n\nThe Group’s fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its [hLAB](https://hlabservices.com/) brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.\n\nhVIVO runs challenge trials in London – its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world’s largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its [FluCamp](http://www.flucamp.com/) volunteer screening facilities in London and Manchester.\n\nFor further information please contact:\n\nhVIVO plc\n\n+44 (0) 20 7756 1300\n\nYamin ‘Mo’ Khan, Chief Executive Officer\n\nStephen Pinkerton, Chief Financial Officer"}